This is the first attempt of its kind on wearable technology and will be attended by thousands of volunteers.
Volunteers in Phase III clinical trials for the Covid-19 vaccine will be offered a free portable device to track their fitness and health. It will help them self-monitor their daily heart and respiratory rates, sleep performance and recovery rate, and measure other important biometric data during the studies.
This is the first attempt of its kind with wearable technology and will be attended by thousands of volunteers.
It follows a collaboration between Abu Dhabi-based G42 Healthcare and Boston-based wearable technology company – Whoop.
The initiative ensures that volunteers who are now taking part in clinical trials at Adnec in Abu Dhabi and at the Al Qarain Center in Sharjah, including those coming for the second dose, can further enhance their volunteer journey using the new portable devices.
Ashish Koshy, CEO of G42 Healthcare, said, "As a digital company, this new partnership is a natural extension of the advanced AI and supercomputing solutions we are already using in the testing process. New volunteers are invited to delve into the technology developed by Whoop, who enhance their individual volunteering experience. "
"We believe that the ability for volunteers to use the Whoop Strap 3.0 wearable device will increase their confidence in the study by giving them the ability to review multiple daily health data points. This will complement the world-class clinical expertise of health professionals. " in the UAE care for the volunteers and ensure their safety and wellbeing throughout the process process. "
"Whoop is proud to partner with G42 Healthcare and participate in the innovative Phase III Covid-19 vaccine trial," said Will Ahmed, Founder and CEO of Whoop. "The Continuous Biometric Monitoring offered by Whoop helps volunteers assess changes in their health and track their daily fitness levels. This partnership represents the future of healthcare: using continuous monitoring and artificial intelligence to improve the effectiveness of drugs, vaccines and medicines to understand other treatments. "
The studies began on July 16 in Abu Dhabi and are administered by G42 Healthcare in partnership with the Ministry of Health – Abu Dhabi, the Ministry of Health and Prevention of the United Arab Emirates (Mohap) and the Abu Dhabi Health Services Company (Seha).